Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972062 | 0.92 | DDB1 (0.50) | DDB1CRBNALDH1A1KDM4EADRA2A | |
| SCHEMBL15633074 | 0.76 | DDB1 (0.33) | DDB1CRBNOPRM1OPRL1PDGFRB | |
| SCHEMBL21495203 | 0.73 | KDM4E (0.41) | DDB1CRBNALDH1A1KDM4EADRA2A | |
| SCHEMBL11731794 | 0.73 | ALDH1A1 (0.45) | DDB1CRBNALDH1A1KDM4EADRA2A | |
| SCHEMBL31388779 | 0.72 | DDB1 (0.32) | DDB1CRBN | |
| SCHEMBL1928183 | 0.72 | CRBN (0.42) | DDB1CRBNALDH1A1KDM4EADRA2A | |
| SCHEMBL22623722 | 0.70 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL18583509 | 0.70 | — | — | |
| SCHEMBL211656 | 0.70 | — | — | |
| SCHEMBL31267020 | 0.69 | RAB9A (0.38) | DDB1CRBNALDH1A1KDM4EADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| CN-119630670-A | Modulators of TNFalpha activity and uses thereof | 瑞雷拉公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025038927-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| CN-109415381-A | Thiazolopyridine derivatives as GPR119 agonist | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1907387-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | DDB1 3126/4885CRBN 3939/4885ALDH1A1 2619/4885 |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | DDB1 3126/4885CRBN 3939/4885ALDH1A1 2619/4885 |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | DDB1 4533/4885CRBN 3824/4885ALDH1A1 1682/4885 |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | DDB1 4661/4885CRBN 2242/4885ALDH1A1 1936/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | DDB1 3126/4885CRBN 3939/4885ALDH1A1 2619/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | DDB1 4591/4885CRBN 4101/4885ALDH1A1 1508/4885 |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | DDB1 4201/4885CRBN 4161/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.